{
    "2019-05-15": [
        [
            {
                "time": "2019-05-15",
                "original_text": "Pfizer Oncology to Showcase New Data from Innovative Science That Address Patient Needs at ASCO 2019 Annual Meeting",
                "features": {
                    "keywords": [
                        "Pfizer",
                        "Oncology",
                        "Innovative Science",
                        "ASCO 2019"
                    ],
                    "sentiment_score": 0.8,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "healthcare",
                        "pharmaceuticals"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": "neutral"
                }
            },
            {
                "time": "2019-05-15",
                "original_text": "After Hours Most Active for May 15, 2019: ARE, NEM, MRC, PFE, SQ, F",
                "features": {
                    "keywords": [
                        "Most Active",
                        "PFE"
                    ],
                    "sentiment_score": 0.6,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "diverse"
                    ],
                    "causal_factor": "false",
                    "causal_impact": "neutral",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2019-05-15",
                "original_text": "This Dow Jones Pharma Giant Is Now A 'Top Pick' — Here's Why",
                "features": {
                    "keywords": [
                        "Dow Jones",
                        "Pharma Giant",
                        "Top Pick"
                    ],
                    "sentiment_score": 0.9,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "pharmaceuticals"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": "neutral"
                }
            },
            {
                "time": "2019-05-15",
                "original_text": "Dow Movers: CAT, KO",
                "features": {
                    "keywords": [
                        "Dow Movers",
                        "CAT",
                        "KO"
                    ],
                    "sentiment_score": 0.7,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "industrial goods",
                        "consumer goods"
                    ],
                    "causal_factor": "false",
                    "causal_impact": "neutral",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2019-05-15",
                "original_text": "Teva Hits Fibonacci Support on Concerns Over Lawsuit",
                "features": {
                    "keywords": [
                        "Teva",
                        "Fibonacci Support",
                        "Lawsuit"
                    ],
                    "sentiment_score": -0.6,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "pharmaceuticals"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "negative",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "negative"
                }
            },
            {
                "time": "2019-05-15",
                "original_text": "The Zacks Analyst Blog Highlights: Teva, Mylan, Novartis and Pfizer",
                "features": {
                    "keywords": [
                        "Zacks Analyst Blog",
                        "Teva",
                        "Mylan",
                        "Novartis",
                        "Pfizer"
                    ],
                    "sentiment_score": 0.5,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "pharmaceuticals"
                    ],
                    "causal_factor": "false",
                    "causal_impact": "neutral",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2019-05-15",
                "original_text": "Pfizer's Bavencio+Inlyta Combo Gets FDA Nod for Kidney Cancer",
                "features": {
                    "keywords": [
                        "Pfizer",
                        "Bavencio",
                        "Inlyta",
                        "FDA",
                        "Kidney Cancer"
                    ],
                    "sentiment_score": 0.9,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "healthcare",
                        "pharmaceuticals"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": "neutral"
                }
            },
            {
                "time": "2019-05-15",
                "original_text": "AbbVie Settles Humira Litigation With Boehringer Ingelheim",
                "features": {
                    "keywords": [
                        "AbbVie",
                        "Humira",
                        "Litigation",
                        "Boehringer Ingelheim"
                    ],
                    "sentiment_score": 0.7,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "pharmaceuticals"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2019-05-15",
                "original_text": "Eli Lilly and Company (LLY) Ex-Dividend Date Scheduled for May 16, 2019",
                "features": {
                    "keywords": [
                        "Eli Lilly",
                        "Ex-Dividend Date"
                    ],
                    "sentiment_score": 0.6,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "pharmaceuticals"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2019-05-15",
                "original_text": "The Daily Biotech Pulse: FDA Greenlights Pfizer-Merck KGAa's Kidney Cancer Combo Treatment, Adcom Disappointment For Daiichi",
                "features": {
                    "keywords": [
                        "FDA",
                        "Pfizer",
                        "Merck",
                        "Kidney Cancer",
                        "Adcom",
                        "Daiichi"
                    ],
                    "sentiment_score": 0.8,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "healthcare",
                        "pharmaceuticals"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": "neutral"
                }
            },
            {
                "time": "2019-05-15",
                "original_text": "Pfizer's atopic dermatitis treatment meets goals in late-stage study",
                "features": {
                    "keywords": [
                        "Pfizer",
                        "atopic dermatitis",
                        "late-stage study"
                    ],
                    "sentiment_score": 0.8,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "healthcare",
                        "pharmaceuticals"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": "neutral"
                }
            },
            {
                "time": "2019-05-15",
                "original_text": "Matinas BioPharma Announces a Research Collaboration with ViiV Healthcare to Evaluate Formulation of Antiviral Drug Candidates",
                "features": {
                    "keywords": [
                        "Matinas BioPharma",
                        "ViiV Healthcare",
                        "Antiviral Drug Candidates"
                    ],
                    "sentiment_score": 0.7,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "biotechnology",
                        "healthcare"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": "neutral"
                }
            },
            {
                "time": "2019-05-15",
                "original_text": "Pfizer dermatitis treatment meets main goals of late-stage study",
                "features": {
                    "keywords": [
                        "Pfizer",
                        "dermatitis",
                        "late-stage study"
                    ],
                    "sentiment_score": 0.8,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "healthcare",
                        "pharmaceuticals"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": "neutral"
                }
            },
            {
                "time": "2019-05-15",
                "original_text": "Pfizer Announces Positive Top-Line Results from Phase 3 Study of Investigational Oral JAK1 Candidate, Abrocitinib (PF-04965842), in Patients Aged 12 and Older with Moderate to Severe Atopic Dermatitis",
                "features": {
                    "keywords": [
                        "Pfizer",
                        "Phase 3",
                        "Abrocitinib",
                        "Atopic Dermatitis"
                    ],
                    "sentiment_score": 0.9,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "healthcare",
                        "pharmaceuticals"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": "neutral"
                }
            },
            {
                "time": "2019-05-15",
                "original_text": "FDA Approves BAVENCIO® (avelumab) plus Axitinib Combination for Patients with Advanced Renal Cell Carcinoma",
                "features": {
                    "keywords": [
                        "FDA",
                        "BAVENCIO",
                        "Avelumab",
                        "Axitinib",
                        "Renal Cell Carcinoma"
                    ],
                    "sentiment_score": 0.9,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "healthcare",
                        "pharmaceuticals"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": "neutral"
                }
            }
        ]
    ]
}